Publications

Antimicrobial Activity of Ceftaroline against Bacteria Isolated in 2008 from Community-acquired Respiratory Tract Infections in European Hospitals, Including Methicillin-resistant Staphylococcus aureus, Lead author: Sader HS, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Spectrum and Potency of Ceftobiprole Against Leading North American Pathogens Producing Community- and Hospital-Acquired Pneumonia (2005-2007), Lead author: Jones RN, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Antimicrobial Activity of Ceftobiprole, a Novel Anti-Methicillin Resistant S. aureus (MRSA) Cephalosporin, Tested Against Skin and Skin Structure Infection Pathogens (North America), Lead author: Jones RN, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Antimicrobial Characterization of CEM-101: Activity against Staphylococci, Beta-haemolytic and Viridans group streptococci, Lead author: Jones RN, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Activity of CEM-101 Tested Against Emerging Telithromycin-Resistant Beta-Haemolytic Streptococci (BHS), Lead author: Jones RN, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Novel PER-variant ß-lactamase identified in Providencia rettgeri strain from the United States (USA): Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Castanheira M, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Pharmacodynamically-linked Variable for the Combination of Ceftaroline plus Novexel104, Lead author: Drusano GL, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Update on the Spectrum and Potency of Tigecycline Tested against 7,133 Gram-positive and -negative Pathogens from 13 Countries (2008), Lead author: Biedenbach DJ, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Worldwide activity of Tigecycline against Community-acquired Respiratory Tract Infection Pathogens Collected During 2006-2008, Lead author: Biedenbach DJ, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Report of Linezolid Resistance from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program (Europe, Latin America, Asia Pacific), Lead author: Ross JE, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Update on daptomycin activity and spectrum when tested against Gram-positive strains collected in European medical centres (2007-2008), Lead author: Sader HS, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Potent Antimicrobial Activity of Daptomycin Tested against Staphylococcus aureus with Vancomycin MIC of 2 mg/L Isolated in United States and European hospitals (2006-2008), Lead author: Sader HS, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Prevalence of Extended-spectrum Beta-lactamases among Enterobacteriaceae Strains from the United States (USA; 2007) and Correlation with KPC Carbapenemases, Lead author: Castanheira M, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Prevalence and Antimicrobial Susceptibility Patterns of Methicillin-resistant S. aureus and Vancomycin-resistant E. faecium Causing Bloodstream Infections in European Hospitals (2005-2008), Lead author: Sader HS, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Telavancin Activity against S. aureus and Coagulase-negative Staphylococci Collected from Clinical Infections in Europe (2007-2008), Lead author: Rhomberg PR, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Antimicrobial Activity of Telavancin Tested against Streptococcal Species Isolates Collected from European Medical Centres (2007-2008), Lead author: Rhomberg PR, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Telavancin Antimicrobial Activity when Tested against Enterococci and Uncommonly Isolated Gram-positive Species (European Sample for 2007-2008), Lead author: Rhomberg PR, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Ten-year trend in aminoglycoside resistance from a worldwide collection of Gram-negative pathogens (1998-2007), Lead author: Biedenbach DJ, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Surveying Aminoglycoside Resistance Mechanisms: a Tool for the Development of Neoglycosides, Lead author: Armstrong, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Anti-pseudomonal Activity of Piperacillin/tazobactam: More than a Decade of Experience from the SENTRY Antimicrobial Surveillance Program (1997-2007), Lead author: Jones RN, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Detection of cfr-carrying Staphylococcus spp. Isolates Recovered from Blood Cultures in a Spanish Hospital During a Phase III Clinical Trial of Topical Omiganan 1% Gel Versus 10% Povidone Iodine, Lead author: Mendes RE, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Extended Studies of Piperacillin/tazobactam Generic Formulations: Variations of Branded Product Lots and Assessment of 38 Generic Lots, Lead author: Jones RN, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Antimicrobial Activity of the Novel Cephalosporin Ceftaroline Tested Against Gram-positive Organisms Causing Skin and Skin Structure Infections (SSSI) Isolated in USA and European Medical Centers in 2008, Lead author: Sader HS, presented at 29th annual Surgical Infection Society (SIS), May 5 – 8, 2009, Chicago, IL

Activity of Daptomycin (DAP) and Comparators Tested Against Gram-positive (GP) Organisms from Bacteremia, Lead author: Sader HS, presented at XIV annual Pan American Congress of Infectology, April 25 – 28, 2009, Sao Paulo, Brazil

Daptomycin Activity against Gram-positive Bacteria Causing Skin and Skin Structure Infections (SSSI), Lead author: Andrade SS, presented at XIV annual Pan American Congress of Infectology, April 25 – 28, 2009, Sao Paulo, Brazil

High prevalence of Macrolide-Lincosamide Resistance in Streptococcus agalactiae in the Asia-Pacific Region; a SENTRY Antimicrobial Surveillance Program Report, Lead author: Bell JM, presented at 7th annual International Symposium on Antimicrobial Agents and Resistance (ISAAR), March 18 – 20, 2009, Bangkok, Thailand

Prevelance of Mupirocin Resistance in Staphylococcus spp. In the Asia-Pacific Region (2004; 2006-2008); A SENTRY Antimicrobial Surveillance Program Report, Lead author: Bell JM, presented at 7th annual International Symposium on Antimicrobial Agents and Resistance (ISAAR), March 18 – 20, 2009, Bangkok, Thailand

Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus arueus. by Sader HS, Rhomberg PR and Jones RN published in Antimicrob. Agents Chemother. 2009; 53 (7): 3162-3165

Activity of contemporary antifungal agents, including the novel Echinocandin Anidulafungin, tested against Candida spp., Cryptococcus Spp., and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007) by Messer SA, Moet GJ, Kirby JT, and Jones RN published in J. Clin. Microbiol. 2009; 47(6):1942-1946

Correlation of cefoxitin MICs with presence of mecA in Staphylococcus spp. by Swenson JM, Brasso WB, Ferraro MJ, Hardy DJ, Knapp CC, Lonsway D, McAllister S, Reller LB, Sader HS, Shortridge D, Skov R, Weinstein MP, Zimmer BL, Patel published in J. Clin. Microbiol. 2009; 47 (6): 1902-1905

Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: Results from the DECIDE Surveillance Program (2007) by Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect Dis. 2009; 64 (2): 177-184

ZAAPS International Surveillance Program (2007) for linezolid resistance: results for 5591 Gram-positive clinical isolates in 23 countries. by Jones RN, Kohno S, Ono Y, Ross JE and Yanagihara K published in Diagn. Microbiol. Infect. Dis. 2009; 64 (2): 191-201

Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respirator tract and skin and skin structures, including recent pharmacodynamic considerations. by Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2009; 64 (2):202-212

In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant Gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. by Vidaillac C, Leonard SN, Sader HS, Jones RN and Rybak MJ published in Antimicrob. Agents Chemother. 2009; 53 (6): 2360-2366

Dissemination of a bla_VIM-2-Carrying Integron Among Enterobacteriaceae species in Mexico: Report from the SENTRY Antimicrobial Surveillance Program. by Morfin-Otero R, Rodriguez-Nkoriega E, Desphande LM, Sader HS, Castanheira M published in Microbial. Drug Resistance. 2009; 15 (1): 33-35

TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens by Jones RN, Moet GJ, Sader HS, Mendes RE and Castanheira M published in J. Antimicrob. Chemother. 2009; 63 (4): 716-720

Clonal dissemination of two clusters of Acinetobacter baumannii producing OXA-23 or OXA-58 in Rome, Italy. by Mendes RE, Spanu T, Deshpande L, Castanheira M, Jones RN, Fadda G published in Clin. Microbiol. Infect. 2009; 15 (6): 588-592

Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: Coping with antimicrobial susceptibility in an era of resistance. by Weinstein MP, Klugman KP and Jones RN published in Clin. Infect. Dis. 2009; 48 (11): 1596-1600

Potency and bactericidal activity of iclaprim against Gram-positive isolates. by Sader HS, Fritsche TR and Jones RN published in Antimicrob. Agents Chemother. 2009; 53 (5): 2171-2175

In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens by Jones RN, Bell JM, Sader HS, Turnidge JD and Stilwell MG published in Diagn. Microbiol. Infect. Dis. 2009; 63 (4): 434-439

Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: Results from a global surveillance study (2003-2007). by Fritsche TR, Sader HS, Stillwell MG, Jones RN published in Diagn. Microbiol. Infect. Dis. 2009; 63 (4): 440-446

Antimicrobial activities of doripenem and other carbapenems against Pseudmonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. by Castanheira M, Jones RN, Livermore DM published in Diagn. Microbiol. Infect. Dis. 2009; 63 (4): 426-433

Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents. by Mendes RE, Rhomberg PR, Bell JM, Turnidge JD, Sader HS published in Diagn. Microbiol. Infect. Dis. 2009; 63 (4): 415-425

Antimicrobial activity of daptomycin and selected comparators tested against bloodstream Staphylococcus aureus isolates from hemodialysis patients. by Sader HS, Fritsche TR, Jones RN published in Int. J. Infect. Dis. 2009; 13 (2): 291-295

In vitro activity of iclaprim and comparison agents tested against Neisseria gonorrhoeae including medium growth supplement effects. by Jones RN, Biedenbach DJ and Sader HS published in Diagn. Microbiol. Infect. Dis. 2009; 63 (3): 339-341

Carbapenem resistance among Pseudmonas aeruginosa strains form India: Evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). by Castanheira M, Bell JM, Turnidge JD, Mathai D and Jones RN published in Antimicrob. Agents Chemother. 2009; 53 (3): 1225-1227

Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler’s diarrhea. by Fritsche TR, Biedenbach DJ and Jones RN published in Antimicrob. Agents Chemother. 2009; 53 (3): 1221-1224

Codetection of bla_OXA-23-like gene (bla_OXA-133) and bla_OXA-58 in Acintobacter radioresistens: Report from the SENTRY Antimicrobial Surveillance Program. by Mendes RE, Bell JM, Turnidge JD, Castanheira M, Deshpande LM and Jones RN published in Antimicrob. Agents Chemother. 2009; 53 (2): 843-844

A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp. by Diekema DJ, Messer SA, Hollis RJ, Boyken L, Tendolkar S, Kroeger J, Jones RN and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2009; 233 (2): 233-236

Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemased among Acinetobacter spp. in Asia-Pacific nations: Report from the SENTRY Surveillance Program. by Mendes RE, Bell JM, Turnidge JD, Castanheira M, and Jones RN published in J. Antimicrob. Chemother. 2009; 63 (1): 55-59